Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

nt of breakthrough medicines to treat oncology, CNS and autoimmune disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 162 people, including 53 PhDs. Selvita has currently several internal projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2014. The most advanced programs at Selvita are SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in hematopoietic tumors and SEL120, first-in-class small molecule inhibitor of cyclin dependent kinase CDK8. Other innovative projects currently in development include SEL141, an early stage discovery program of DYRK1A kinase inhibitors with therapeutic potential in the treatment targeting Alzheimer's disease and Down syndrome, SEL201 – novel small molecule MNK1/2 inhibitors in oncology, cancer metabolism platform and inflammasome platform.  Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita is listed on the NewConnect market of the Warsaw Stock Exchange in Poland (SLV). Additional information about Selvita can be found on http://www.selvita.com/

Media Contacts:

Mike Beyer
Sam Brown Inc.
(773) 463-4211
beyer@sambrown.com

Paulina Wolanin
+48 668 111 456
paulina.wolanin@selvita.com


'/>"/>
SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical ... presentations at three investor conferences: , Wednesday, September ... in New York at the New ... PM at the BioCentury NewsMakers Conference in New ... Center , Thursday, September 17 at 9:30 AM at ...
(Date:9/2/2015)... Wellinton, Florida (PRWEB) , ... September 02, 2015 ... ... has been treated and managed with the use of special anti-vascular endothelial growth ... occurs in many more patients, currently does not have a scientific protocol for ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... of botanical and plant-derived compounds. BCC Research reveals in its new report ... because this market defines the category and generates the most market demand. ...
(Date:9/2/2015)... Israel , September 2, 2015 ... TASE: BOLT) ("BioLight" or the "Company"), a firm ... in ophthalmology and cancer diagnostics, announced today that ... of glaucoma will be delivered at the Ophthalmology ... the European Society of Cataract & Refractive Surgeons ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... $40 Million ... , ... 18, 2010 -- DuPont announced plans to expand its cutting-edge plant genetics research to help ... in central Iowa with additional lab facilities and jobs focused on advanced plant genetics., , ...
... ... Voxel Tracker™ is first-of-its-kind , ... Pittsburgh, PA (Vocus) March 18, 2010 -- Celsense, Inc. ... The software, dubbed Voxel Tracker™, was designed to optimize the use of Celsense’ ...
... experimenters three years to believe, University of Michigan engineers ... twist ribbons of nanoparticles. The results are published ... Matter readily bends and twists light. That,s the mechanism ... the opposite interaction has rarely been observed, said Nicholas ...
Cached Biology Technology:DuPont to Expand Plant Genetics Research Facilities 2DuPont to Expand Plant Genetics Research Facilities 3Novel Imaging Software Released by Celsense Inc. 2Novel Imaging Software Released by Celsense Inc. 3Light twists rigid structures in unexpected nanotech finding 2Light twists rigid structures in unexpected nanotech finding 3
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a prominent smartphone manufacturer in ... selected FPC1 155 for ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... a pack of lionesses chasing down a lonely gazelle ... bacteria. Working with colleagues at Caltech, Stanford and ... has developed a living system using genetically altered bacteria ... the population levels of prey influence the levels of ...
... DIEGO Genetic variations ensure that no two people ... have the tools and the knowledge to predict how ... and effective treatment. At the 2008 Annual Meeting of ... 16, researchers present data on new biomarkers that can ...
... 1:00 p.m. ET) Research published in Nature Chemical Biology ... pathway, termed necroptosis, all target and inhibit RIP1 kinase, ... by trauma such as a heart attack or stroke, ... damage contributing to death or long-term disability. The findings ...
Cached Biology News:Novel living system recreates predator-prey interaction 2Novel living system recreates predator-prey interaction 3Biomarkers allow doctors to match therapy to patient 2Biomarkers allow doctors to match therapy to patient 3Biomarkers allow doctors to match therapy to patient 4Biomarkers allow doctors to match therapy to patient 5Biomarkers allow doctors to match therapy to patient 6Biomarkers allow doctors to match therapy to patient 7Stopping unwanted cell death: Implications for drug discovery 2Stopping unwanted cell death: Implications for drug discovery 3